Thermo Fisher Scientific Deferred Tax Assets decreased by 117.3% to -$258.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 124.8%, from $1.04B to -$258.00M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows an upward trend with a 6.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase can signal future tax efficiency or the utilization of past losses, while a decrease may indicate the realization of those benefits.
These are assets on the balance sheet that represent future tax savings resulting from temporary differences between the...
Common in large, capital-intensive companies; peers with significant R&D spending often have large deferred tax assets from tax credits.
deferred_tax_assets| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.63B | $1.47B | $2.83B | $3.49B | $3.33B | $3.14B | $1.98B | $2.98B | $2.84B | $2.62B | $1.92B | $1.81B | $1.52B | $1.12B | $1.27B | $1.04B | $624.00M | $842.00M | $1.49B | -$258.00M |
| QoQ Change | — | -10.2% | +93.1% | +23.5% | -4.8% | -5.6% | -36.8% | +50.0% | -4.5% | -7.8% | -26.6% | -5.8% | -16.3% | -25.9% | +12.9% | -17.9% | -40.1% | +34.9% | +77.3% | -117.3% |
| YoY Change | — | — | — | — | +103.9% | +114.3% | -29.9% | -14.8% | -14.6% | -16.6% | -3.1% | -39.1% | -46.7% | -57.1% | -34.0% | -42.5% | -58.8% | -25.0% | +17.7% | -124.8% |